Shl Medical
Shl Medical, a leading player in the medical device industry, is headquartered in Switzerland and operates extensively across Europe, North America, and Asia. Founded in 1985, the company has established itself as a pioneer in the development and manufacturing of advanced drug delivery systems, particularly prefilled syringes and auto-injectors. Shl Medical's innovative approach combines cutting-edge technology with user-centric design, ensuring that their products not only meet regulatory standards but also enhance patient experience. With a strong commitment to quality and sustainability, the company has achieved significant milestones, including partnerships with major pharmaceutical firms. Recognised for its expertise, Shl Medical continues to solidify its market position as a trusted provider of medical solutions, contributing to improved healthcare outcomes worldwide.
DitchCarbon Score
How does Shl Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shl Medical's score of 41 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shl Medical's reported carbon emissions
In 2023, SHL Medical reported total greenhouse gas (GHG) emissions of approximately 43.3 million tonnes CO2e from Scope 1, 0.44 million tonnes CO2e from Scope 2, and about 246.6 million tonnes CO2e from Scope 3 emissions. This represents a slight increase in Scope 1 emissions from 42.9 million tonnes CO2e in 2022, while Scope 2 emissions decreased from 0.63 million tonnes CO2e. Scope 3 emissions also saw a reduction from 254.5 million tonnes CO2e in the previous year. SHL Medical has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030, using 2022 as the base year. Additionally, the company targets a 51.6% reduction in Scope 3 emissions related to purchased goods and services, employee commuting, and downstream transportation and distribution per million units sold within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are consistent with efforts to limit global warming to 1.5°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
|---|---|---|
| Scope 1 | 42,973,000 | 00,000,000 |
| Scope 2 | 633,000 | 000,000 |
| Scope 3 | 254,504,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shl Medical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
